Omeros Corporation
OMERHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOmeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company carries a $1.20B market cap, placing it firmly in the small-cap category. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Market Cap
$1.20B
Beta
2.57
P/E (TTM)
13.58
P/E (Fwd)
13.47
EPS (TTM)
$1.22
EPS (Fwd)
$1.23
ROE
—
ROA
-18.7%
Cash
$132.0M
Total Debt
$296.9M
Free CF
$183.3M
52W Change
114.9%
Annual Financials
Cash vs Debt
Where OMER stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, OMER finished 18.08% above its 150-day moving average ($13.72) and 21.53% above its 200-day moving average ($13.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OMER overbought or oversold?
At the October 19, 2026 close, OMER's RSI(14) was 28.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $132.0M in cash, though total debt stands at $296.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $183.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing.
A beta of 2.57 means OMER is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Omeros Corporation and its sector.